- Home
- ADPT
as 07-26-2024 4:00pm EST
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Upcoming Earnings Alert:
Get ready for potential market movements as Adaptive Biotechnologies Corporation ADPT prepares to release earnings report on 01 Aug 2024.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 514.3M | IPO Year: | 2019 |
| Target Price: | $6.20 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.28 - $8.51 | Next Earning Date: | 08-01-2024 |
| Revenue: | $174,502,000 | Revenue Growth: | -5.33% |
| Revenue Growth (this year): | 0.55% | Revenue Growth (next year): | 22.46% |
Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BENZENO SHARON | ADPT | Chief Commercial Ofc Imm Med | Mar 4 '24 | Sell | $3.44 | 18,644 | $64,135.36 | 327,415 | SEC Form 4 |
| BENZENO SHARON | ADPT | Chief Commercial Ofc Imm Med | Mar 4 '24 | Sell | $3.43 | 10,746 | $36,858.78 | 346,059 | SEC Form 4 |
| Taylor Stacy L | ADPT | SVP and General Counsel | Mar 4 '24 | Sell | $3.44 | 6,609 | $22,734.96 | 166,287 | SEC Form 4 |
| Taylor Stacy L | ADPT | SVP and General Counsel | Mar 4 '24 | Sell | $3.43 | 6,772 | $23,227.96 | 172,896 | SEC Form 4 |
| RUBINSTEIN JULIE | ADPT | President | Mar 4 '24 | Sell | $3.56 | 13,490 | $48,024.40 | 472,754 | SEC Form 4 |
| RUBINSTEIN JULIE | ADPT | President | Mar 4 '24 | Sell | $3.43 | 25,580 | $87,739.40 | 486,244 | SEC Form 4 |
| LO FRANCIS | ADPT | Chief People Officer | Mar 4 '24 | Sell | $3.44 | 1,813 | $6,236.72 | 253,745 | SEC Form 4 |
| LO FRANCIS | ADPT | Chief People Officer | Mar 4 '24 | Sell | $3.43 | 12,887 | $44,202.41 | 255,558 | SEC Form 4 |
| PISKEL KYLE | ADPT | Principal Accounting Officer | Mar 4 '24 | Sell | $3.43 | 7,727 | $26,503.61 | 123,318 | SEC Form 4 |
| PETERSON TYCHO | ADPT | Chief Financial Officer | Mar 4 '24 | Sell | $3.44 | 15,456 | $53,168.64 | 531,553 | SEC Form 4 |
| ROBINS CHAD M | ADPT | CEO and Chairman | Mar 4 '24 | Sell | $3.44 | 5,879 | $20,223.76 | 2,619,495 | SEC Form 4 |
| ROBINS CHAD M | ADPT | CEO and Chairman | Mar 4 '24 | Sell | $3.43 | 42,794 | $146,783.42 | 2,576,701 | SEC Form 4 |
| BOBULSKY SUSAN | ADPT | Chief Commercial Officer, MRD | Mar 4 '24 | Sell | $3.43 | 6,016 | $20,634.88 | 255,265 | SEC Form 4 |
| BOBULSKY SUSAN | ADPT | Chief Commercial Officer, MRD | Mar 4 '24 | Sell | $3.44 | 6,975 | $23,994.00 | 248,290 | SEC Form 4 |
| PISKEL KYLE | ADPT | Principal Accounting Officer | Nov 16 '23 | Sell | $4.13 | 259 | $1,069.67 | 87,305 | SEC Form 4 |
Latest Adaptive Biotechnologies Corporation News
ADPT Breaking Stock News: Dive into ADPT Ticker-Specific Updates for Smart Investing
TechCrunch
11 days ago
Adaptive builds automation tools to speed up construction payments
GlobeNewswire
15 days ago
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Zacks
17 days ago
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
Yahoo Finance Video
2 months ago
FDA panel votes to recommend Eli Lilly's Alzheimer's drug
GlobeNewswire
2 months ago
Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis
Reuters
2 months ago
California seeks company profits in Big Oil climate lawsuit
USA TODAY
2 months ago
S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead
Business Wire
2 months ago
Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
Compare ADPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADPT Adaptive Biotechnologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.